000			01496cam a22003017a 4500
001			15393936
003			OSt
005			20150625124048.0
008			080802s2008 dcu b 000 0 eng d
010			_a 2008298577
020			_a9780309118668
040			_aSEKU
050	0	0	_aRA 644.I6 _bI57
110	2		_aInstitute of Medicine (U.S.). _bCommittee on Implementation of Antiviral Medication Strategies for an Influenza Pandemic.
245	1	0	_aAntivirals for pandemic influenza : _bguidance on developing a distribution and dispensing program _cCommittee on Implementation of Antiviral Medication Strategies for an Influenza Pandemic, Board on Population Health and Public Health Practice, Institute of Medicine of the National Academies.
260			_aWashington, DC : _bNational Academies Press, _cc2008
300			_a122 p.
504			_aIncludes bibliographical references (p. 87-92).
505	0		_aIntroduction -- Antiviral effectiveness, safety, and supply -- Ethics, decision making, and communication ethics -- Who should get antivirals and where?
536			_aSupported by the National Academy of Sciences and the Dept. of Health and Human Services _bHHSP 23320042509X1 _gHHSP233200700006T
650		0	_aInfluenza _zUnited States _xEpidemiology.
650		0	_aInfluenza _xVaccination _zUnited States.
650		0	_aInfluenza _xPrevention.
650		0	_aAntiviral agents.
650		0	_aAntiviral agents _xEffectiveness.
650		0	_aEpidemics _xPrevention.
942			_2lcc _cGEN
999			_c4288 _d4288